Table 2.
Effects of CD80 and CD86 blockade on graft survival
| Treatment | Cardiac allograft survival |
|---|---|
| Control Ig | 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8 |
| DST | 11, 12, 12, 13, 19, 20, 20 |
| CTLA4Ig + DST | >150 (n = 12) |
| Anti-B7-1 + DST | 20, 22, 23, 42, 42 |
| CTLA4IgY100F + DST | 5, 5, 7, 11, 16 |
| Anti-CD86 + DST | 7, 25, 28, 100+, 100+ |
| CTLA4IgY100F + anti-CD86 + DST | >150 (n = 4) |
BALB/c hearts were transplanted into C57BL/6 recipients. Allograft recipients were treated with a control Ig, anti-CD80 mAb, or anti-CD86 mAb (200 μg by intravenous injection), CTLA4Ig (200 μg), or CTLA4IgY100F (600 μg) 2 days after transplantation. Selected recipients also received a transfusion of 5 × 106 donor lymphocytes (DST) at the time of transplantation.